https://orcid.org/0000-0002-8370-9562
References
- Al Meslamani AZ, Sammani N. Assessment of changes in the epidemiology and prognosis of non-SARS-CoV-2 respiratory infections one year after recovery from COVID-19. Respir Investig [Internet]. 2023;61(4):445–453. Available from: https://www.sciencedirect.com/science/article/pii/S2212534523000369
- Al Meslamani AZ. Antibiotic resistance in low- and middle-income countries: current practices and its global implications. Expert Rev Anti Infect Ther [Internet]. 2023 Dec 2;21(12):1281–1286. doi: 10.1080/14787210.2023.2268835
- Al Meslamani AZ. Will SARS-CoV-2 impact the incidence and nature of other respiratory infections? Expert Rev Clin Immunol [Internet]. 2023 Dec 2;19(12):1431–1434. doi: 10.1080/1744666X.2023.2263646
- Müller C, Reuter S, Wille J, et al. A global view on carbapenem-resistant Acinetobacter baumannii. MBio. 2023 Oct;14(6):e0226023. doi: 10.1128/mbio.02260-23
- Pogue JM, Zhou Y, Kanakamedala H, et al. Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect Dis [internet]. 2022;22(1):36. doi: 10.1186/s12879-021-07024-4
- Iovleva A, Mustapha MM, Griffith MP, et al. Carbapenem-resistant Acinetobacter baumannii in U.S. Hospitals: diversification of circulating lineages and antimicrobial resistance. MBio. 2022 Apr;13(2):e0275921. doi: 10.1128/mbio.02759-21
- Goldenberg SD, Dodgson AR, Barlow G, et al. Epidemiology, outcomes and resource utilisation in patients with carbapenem non-susceptible gram-negative bacteria in the UK: a retrospective, observational study (CARBAR UK). Adv Ther. 2022 Aug;39(8):3602–3615. doi: 10.1007/s12325-022-02177-3
- Khalid F, Saleem S, Ahmad I. High prevalence of carbapenem-resistant Acinetobacter baumannii associated respiratory tract infections in Pakistani hospitals. J Pak Med Assoc. 2020 Sep;70:1–2. doi: 10.5455/JPMA.35384
- El-Ghali A, Kunz Coyne AJ, Caniff K, et al. Sulbactam-durlobactam: a novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections. Pharmacotherapy. 2023 Jun;43(6):502–513. doi: 10.1002/phar.2802
- US FDA. FDA approves new treatment for pneumonia caused by certain difficult-to-treat bacteria [Internet]. 2023 [cited 2024 Jan 31]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria
- Karlowsky JA, Hackel MA, McLeod SM, et al. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother. 2022 Sep;66(9):e0078122. doi: 10.1128/aac.00781-22
- Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, et al. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-i. Lancet Infect Dis [internet]. 2023 Sep 1;23(9):1072–1084. doi: 10.1016/S1473-3099(23)00184-6
- Giuliano S, Sbrana F, Tascini C. Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex. Lancet Infect Dis [Internet]. 2023 Aug 1;23(8):e274. doi: 10.1016/S1473-3099(23)00422-X
- Sagan O, Yakubsevitch R, Yanev K, et al. Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis. Antimicrob Agents Chemother. 2020 Feb;64(3). doi: 10.1128/AAC.01506-19
- Zaidan N, Hornak JP, Reynoso D. Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a Novel Antibiotic Combination. Antimicrob Agents Chemother. 2021 Oct;65(11):e0092421. doi: 10.1128/AAC.00924-21
- Hajek KL, Lovatt AJ, Bhalerao S, et al. 2515. Evaluation of the equivalency of the oxoid sulbactam-durlobactam (10/10µg) antimicrobial disc to the CLSI M07 broth microdilution frozen reference method. Open Forum Infect Dis [Internet]. 2023 Dec 1;10(Supplement_2):ofad500.2133. doi: 10.1093/ofid/ofad500.2133
- Zampaloni C, Mattei P, Bleicher K, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature [Internet]. 2024;625(7995):566–571. doi: 10.1038/s41586-023-06873-0
- Shields RK, Paterson DL, Tamma PD. Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2023 May;76(Suppl 2):S179–93. doi: 10.1093/cid/ciad094